FDA signals potential pathway for testosterone therapy label expansion

The FDA has announced a preliminary step toward potentially expanding the use of testosterone replacement therapy (TRT) to include treatment of low libido in men with idiopathic hypogonadism, a population currently outside labeled indications. The agency is encouraging sponsors of approved TRT products to engage in discussions regarding supplemental new drug applications (sNDAs), citing emerging clinical data that may support efficacy and safety in this setting.

Holders of currently approved TRT NDAs are encouraged to contact the FDA by April 30, 2026.

The move reflects a shift in regulatory openness following internal review and external expert input, though the FDA emphasized that any label expansion would require robust evidence demonstrating a favorable benefit-risk profile.

“New and emerging data suggest there may be an opportunity to help men suffering from symptoms that significantly affect quality of life,” said FDA Commissioner Marty Makary, MD, MPH, in a news release from the agency.¹ “We are eager to work with sponsors to further evaluate this potential new use while upholding our rigorous standards for safety and effectiveness.”

Regulatory background

Currently approved TRT products—including topical gels, transdermal patches, and injectable formulations—are indicated for men with hypogonadism due to known structural or genetic causes.² Patients with idiopathic hypogonadism, characterized by low serum testosterone levels without an identifiable cause, may not meet criteria for TRT under existing FDA labeling.

The FDA’s announcement follows a preliminary review of emerging evidence from published clinical literature as well as expert insight from a panel discussion in December 2025.³ During that meeting, experts suggested that studies have demonstrated signals of benefit in patients with low libido related to idiopathic hypogonadism.

“Sexual health is an important component of overall well-being and quality of life,” added Brian J. Christine, MD, Assistant Secretary for Health, in the news release.¹ “This is an exciting opportunity to build on new science and potentially expand treatment options for men with hypogonadism. We encourage continued innovation and collaboration to bring forward high-quality evidence that can expand options for men with hypogonadism.”

REFERENCES

1. FDA Takes Step Forward on Testosterone Therapy for Men. News release. US Food & Drug Administration. April 16, 2026. Accessed April 16, 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

2. Testosterone information. US Food & Drug Administration. Accessed April 16, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information

3. FDA Expert Panel on Testosterone Replacement Therapy for Men. US Food & Drug Administration. December 10, 2025. Accessed April 16, 2026. https://www.fda.gov/patients/fda-expert-panels/fda-expert-panel-testosterone-replacement-therapy-men-12102025